Search results
'Folded boy' closer to standing straight after risky op to 'unravel' his spine
The US Sun· 18 hours agoJiang Yanchen, 19, from the Shandong province in China, suffers from ankylosing spondylitis, which...
Spondylitis Association of America Announces Virtual Event to Empower Community Living With Chronic...
Digital Journal· 2 days agoThe summit takes place on May 3-4, 2024, offering a comprehensive platform for patients, caregivers, and advocates to come together and advance their understanding of this chronic...
'Folded man' finally gets surgery to stand up straight after 28 years of suffering from rare disease
UNILAD· 5 days agoA man who lived with a condition which left him 'folded over' for years finally had life-changing...
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 2 days agoAs of March, the blockbuster autoimmune drug Humira (adalimumab) still held 96% of the market share...
People Are Sharing Just How Out Of Touch Their Boomer Parents Are
BuzzFeed via Yahoo News· 2 days agoThey shared one, of course." 20."I am 42. I was diagnosed with ulcerative colitis when I was 14. My...
Heel Spur
Health via Yahoo News· 6 days agoA heel spur is a bony growth around your heel bone. You may feel pain around your foot where the heel spur grows. Most symptoms can be treated at home.
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 2 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 3 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 3 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...
